This is the current update in October 2024 after the multi‐society clinical practice guidance by the Surgery for Obesity and Related Diseases, Clinical Gastroenterology and Hepatology and Surgical Endoscopy for safely managing patients needing GLP-1 RAs therapy in type 2 diabetes, overweight and obesity, and heart failure during the periprocedural period [40]. Here, GLP1R is linked to type 2 diabetes mellitus.